the advocacy monitor

Independent Living News & Policy from the National Council on Independent Living

Information Alert: ASPR Speed Monoclonal Antibodies (mAbs) Initiative / Program to Priority Settings

In an effort to make sure NCIL members have as much information about COVID-19 as possible, we want to share some information about a recently approved treatment. The Food and Drug Administration (FDA) has approved monoclonal antibody treatments (mAb) for emergency use to treat people with mild to moderate COVID-19. This treatment is intended to reduce the risk of getting sicker, requiring hospitalization, or dying from COVID. To be eligible for this treatment, a person must:

  • have tested positive for COVID-19
  • have a mild to moderate case of COVID-19
  • be 12 years of age or older
  • be at high risk for progressing to severe COVID-19 and / or hospitalization
  • have had symptoms for 10 days or less

Antibodies are something the body makes to fight infections. Monoclonal antibodies are made in a lab to fight a specific infection. The monoclonal antibodies used in these treatments were developed specifically to fight COVID-19. The monoclonal antibodies are given by infusion.

Speak Your Mind

*